Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C21H24N4O2
CAS Number:
Molecular Weight:
364.44
UNSPSC Code:
12352200
assay
≥97% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, protect from light
color
white
solubility
DMSO: 10 mg/mL, ethanol: 5 mg/mL
shipped in
ambient
storage temp.
2-8°C
Quality Level
Disclaimer
Toxicity: Standard Handling (A)
Biochem/physiol Actions
Cell permeable: yes
Primary Target
PI 3-Kβ
PI 3-Kβ
Product competes with ATP.
Reversible: yes
Target IC50: 0.005, 0.1, 5, and ≥3.5 µM for -β, -δ, -α and -γ isoforms, respectively
General description
A cell-permeable morpholino-pyrimidinone compound that acts as a reversible, ATP-competitive, selective, and highly potent inhibitor of PI 3-Kβ (IC50 = 0.005, 0.1, 5, and ≥3.5 µM for -β, -δ, -α and -γ isoforms, respectively) with little activity against a panel of 15 commonly studied protein kinases even at concentrations as high as 10.0 µM. An excellent tool for studying p110β-dependent responses both in cells in vitro and in animals in vivo.
Other Notes
Chaussade, C., et al. 2007. Biochem. J.404, 449.
Cosemans, J.M, et al. 2006. Blood108, 3045.
Condliffe, A.M., et al. 2005. Blood106, 1432.
Jackson, S.P., et al. 2005. Nat. Med.11, 507.
Cosemans, J.M, et al. 2006. Blood108, 3045.
Condliffe, A.M., et al. 2005. Blood106, 1432.
Jackson, S.P., et al. 2005. Nat. Med.11, 507.
Packaging
Packaged under inert gas
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Storage Class
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Kubra Narci et al.
BMC cancer, 22(1), 320-320 (2022-03-26)
Targeted therapies for Primary liver cancer (HCC) is limited to the multi-kinase inhibitors, and not fully effective due to the resistance to these agents because of the heterogeneous molecular nature of HCC developed during chronic liver disease stages and cirrhosis.
Related Content
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service